Stock screenerAll disclosures →
EDGAR →
CLYM
Conviction 51HealthcareScan · Thu, Sep 24, 2026Climb Bio, Inc. (CLYM) closed at $11.89 (-5.07%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 35, RS Rating 99, -33.4% from its 52-week high, +216.9% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
CLYM$11.89-5.07%
ResistanceSupportVol 14Insider sellVol MA14 1.9M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price11.89
Change-5.07%
Gap-2.36%
Rel volume2.53×
Avg volume2.01M
Avg $ vol28.31M
SMA 2014.32
SMA 5014.22
SMA 2009.51
Price vs 50-16.40%
Price vs 200+24.98%
MA stackmixed
50/200 cross—
Supertrenddown · 15.26
RSI (14)35
MACD hist-0.32
MACD cross—
Stoch %K / %D10 / 17
ADX (14)26
+DI / −DI11 / 31
RSI divergence—
MACD divergence—
ATR %9.61%
ADR %8.01%
52w high17.84
52w low1.64
From 52w high-33.38%
Above 52w low+624.70%
New 52w highNo
SqueezeOff
Bollinger width25.55%
%B-0.17
Donchian pos10.02%
Donchian high16.33
Donchian low11.39
AVWAP (52w high)14.32
vs AVWAP high-16.99%
AVWAP (52w low)8.94
vs AVWAP low+33.00%
OBV trendDown
Chaikin MF (20)-0.11
Today vs 20d2.53×
Avg vol (14d)1.9M
Avg vol (20d)2.01M
Avg $ vol (20d)28.31M
Market cap682.63M
RS Rating99 / 99
RS 3m (vs SPY)-10.61%
RS 6m (vs SPY)+53.45%
RS line new highNo
Trend template5/8
Technical rank60.4
1 week-15.47%
1 month-33.38%
3 months-6.12%
6 months+70.27%
1 year+428.22%
YTD+216.93%
P/E-11.41
P/B2.85
P/S—
P/FCF-12.52
EPS-0.8800
Div yield—
ROE-24.99%
ROA-24.30%
Debt/Eq—
Current31.45
EV/EBITDA-9.42
Gross margin—
Net margin—
Rev growth—
EPS growth19.01%
Price target28.11
Target upside136.52%
Analyst ratingBuy
Institutional101.37%
Ent. value638.52M
Revenue—
Net income-13.5M
Gross profit—
Free cash flow-54.54M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out57.26M
Employees29
ListedTue, Aug 10, 2021
Free float19.95M
Float %41.8%
Short interest7.3M
Days to cover5.9d
Short volume57.7%
Squeeze score92 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.18 vs −$0.22
Last surprise+18.2% beat
Setup gradeC
Conviction51 / 100
Pattern quality—
Tech rank60.4 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance18.23
Support12.23
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Raymond James adds Climb Bio stock to favorites list on drug potentialInvesting.com · Wed, Sep 23, 2026
- Climb Bio, Inc.(NasdaqGM: CLYM) added to S&P Biotechnology Select Industry Indexmarketscreener.com · Mon, Sep 21, 2026
Congress activity
Disclosed STOCK Act trades in CLYM
No recent disclosed trades by Congress in CLYM. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in CLYM · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Thomas Stephen Basil Director · Common Stock · 2026-09-15 | Sell | 100K | $1.4M | 2026-09-15 | 2026-09-17 |
Brennan Aoife President and CEO · Common Stock · 2026-06-29 | Sell | 30.9K | $407K | 2026-06-29 | 2026-06-30 |
Brennan Aoife President and CEO · Restricted Stock Units · 2026-06-27 | Exercise | 68.75K | — | 2026-06-27 | 2026-06-30 |
Brennan Aoife President and CEO · Common Stock · 2026-06-27 | Exercise | 68.75K | — | 2026-06-27 | 2026-06-30 |
Drapkin Kimberlee C Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
WILLIAMS DOUGLAS E Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
Thomas Stephen Basil Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA CAPITAL MANAGEMENT, L.P. Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA Capital Nexus Fund II, L.P. Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA Capital Nexus Fund, L.P. Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
SEC filings
EDGAR filings in CLYM · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.